Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer

被引：0
|
作者：
Struss, Werner J. [1 ]
Black, Peter C. [1 ]
机构：
[1] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC, Canada
来源：
UROLOGY | 2017年 / 109卷
关键词：
THERAPY;
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1 / 2
页数：2
相关论文
共 50 条
  • [31] IMPACT OF TROUGH CONCENTRATIONS OF ABIRATERONE AND D4A ON THE CLINICAL OUTCOMES OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE AND CASTRATION-RESISTANT PROSTATE CANCER
    Takahashi, Yoshiko
    Narita, Shintaro
    Shiota, Masaki
    Kashima, Soki
    Yamamoto, Ryohei
    Koizumi, Atsushi
    Numakura, Kazuyuki
    Saito, Mitsuru
    Eto, Masatoshi
    Miura, Masatomo
    Habuchi, Tomonori
    JOURNAL OF UROLOGY, 2022, 207 (05): : E453 - E453
  • [32] Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer
    Hoyle, A. P.
    Ali, S. A.
    James, N. D.
    Parker, C. C.
    Cook, A. D.
    Attard, G.
    Chowdhury, S.
    Cross, W.
    Dearnaley, D. P.
    de Bono, J. S.
    Gilson, C. E.
    Gillessen, S.
    Jones, R.
    Matheson, D.
    Mason, M. D.
    Ritchie, A.
    Russell, M.
    Parmar, M. K.
    Sydes, M. R.
    Clarke, N. W.
    ANNALS OF ONCOLOGY, 2018, 29 : 722 - 722
  • [33] Bone-Modifying Agents in Patients With High-Risk Metastatic Castration-Sensitive Prostate Cancer Treated With Abiraterone Acetate
    Fukuokaya, Wataru
    Mori, Keiichiro
    Urabe, Fumihiko
    Igarashi, Taro
    Yanagisawa, Takafumi
    Tsuzuki, Shunsuke
    Honda, Mariko
    Miki, Kenta
    Kimura, Takahiro
    JAMA NETWORK OPEN, 2024, 7 (03) : E242467
  • [34] DOES CLINICAL EVIDENCE OF HETEROGENEITY INFLUENCE TREATMENT SELECTION? A CASE STUDY OF ABIRATERONE ACETATE FOR METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
    Jiao, B.
    Nyame, Y.
    Carlson, J. J.
    Garrison, L. P.
    Basu, A.
    VALUE IN HEALTH, 2022, 25 (07) : S481 - S481
  • [35] Abiraterone Acetate, in Combination with Apigenin, Attenuates the Survival of Human Castration-Sensitive Prostate Cancer Cells
    Genc, Fatih
    Atabey, Ugur Simal
    Serttas, Riza
    Erdogan, Suat
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2022, 22 (18) : 3148 - 3156
  • [36] Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration-Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate
    Nishimoto, Mitsuhisa
    De Velasco, Marco A.
    Yamamoto, Yutaka
    Fujimoto, Saizo
    Akashi, Yasunori
    Toyoda, Shingo
    Hashimoto, Mamoru
    Adomi, Shogo
    Banno, Eri
    Saito, Yoshitaka
    Minami, Takafumi
    Hirayama, Akihide
    Yoshimura, Kazuhiro
    Uemura, Hirotsugu
    Fujita, Kazutoshi
    PROSTATE, 2025,
  • [37] COST-EFFECTIVENESS OF ABIRATERONE, ENZALUTAMIDE, AND APALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): A PARTITIONED-SURVIVAL MODEL
    Katta, A.
    Hansen, R. N.
    VALUE IN HEALTH, 2023, 26 (06) : S68 - S68
  • [38] Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study
    Koroki, Yosuke
    Taguri, Masataka
    TARGETED ONCOLOGY, 2023, 18 (01) : 119 - 128
  • [39] Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study
    Yosuke Koroki
    Masataka Taguri
    Targeted Oncology, 2023, 18 : 119 - 128
  • [40] Letter to the Editor: How We Treat Metastatic Castration-Sensitive Prostate Cancer
    Daungsupawong, Hinpetch
    Wiwanitkit, Viroj
    CANCER CONTROL, 2024, 31
12345